Patient-, disease-, and transplant-related characteristics of patients with HL or NHL who underwent allo-HSCT following relapse after autologous transplantation, 1990 to 1999, reported to IBMTR
Variables . | N(%)* . |
|---|---|
| N | 114 |
| Age, y, median (range) | 34 (15-65)† |
| Male | 65 (57) |
| Karnofsky performance score at allo-HSCT | |
| 90%-100% | 64 (56) |
| 80% | 29 (25) |
| 70% | 16 (14) |
| 60% | 2 (2) |
| 50% or lower | 3 (3) |
| Disease type | |
| NHL | 79 (69) |
| Low grade | 16 (20) |
| Intermediate grade | 44 (56) |
| High grace | 8 (10) |
| Other‡ | 11 (14) |
| HL | 35 (31) |
| Interval from diagnosis to first, autologous, transplantation, mo, median (range) | 14 (3-130)† |
| 12 or less | 43 (38) |
| More than 12 | 71 (62) |
| Interval from auto-HSCT to allo-HSCT, mo, median (range) | 16 (2-66)† |
| 12 or less | 44 (39) |
| More than 12 | 70 (61) |
| Disease status before allo-HSCT | |
| Complete remission | 24 (21) |
| Relapse or persistent disease, chemosensitive | 39 (35) |
| Relapse or persistent disease, chemoresistant | 23 (20) |
| Relapse or persistent, untreated after auto-HSCT | 28 (24) |
| Donor type for allo-HSCT | |
| HLA-identical sibling | 70 (61) |
| Haploidentical sibling | 17 (14) |
| Unrelated | 27 (25) |
| Graft type used for allo-HSCT | |
| Bone marrow | 77 (68) |
| Peripheral blood | 37 (32) |
| TBI for allo-HSCT | 45 (39) |
| Posttransplantation use of growth factors, within 7 d | 84 (74) |
| GVHD prophylaxis | |
| MTX + CSA ± others | 74 (65) |
| CSA ± others | 24 (21) |
| T-cell depletion ± others | 16 (14) |
| Years of allo-HSCT | |
| 1990-1996 | 56 (49) |
| 1997-1999 | 58 (51) |
| No. centers reporting | 54 |
| Follow-up time of survivors, mo, median (range) | 43 (3-89)† |
| 75th percentile | 21 |
| 25th percentile | 58 |
Variables . | N(%)* . |
|---|---|
| N | 114 |
| Age, y, median (range) | 34 (15-65)† |
| Male | 65 (57) |
| Karnofsky performance score at allo-HSCT | |
| 90%-100% | 64 (56) |
| 80% | 29 (25) |
| 70% | 16 (14) |
| 60% | 2 (2) |
| 50% or lower | 3 (3) |
| Disease type | |
| NHL | 79 (69) |
| Low grade | 16 (20) |
| Intermediate grade | 44 (56) |
| High grace | 8 (10) |
| Other‡ | 11 (14) |
| HL | 35 (31) |
| Interval from diagnosis to first, autologous, transplantation, mo, median (range) | 14 (3-130)† |
| 12 or less | 43 (38) |
| More than 12 | 71 (62) |
| Interval from auto-HSCT to allo-HSCT, mo, median (range) | 16 (2-66)† |
| 12 or less | 44 (39) |
| More than 12 | 70 (61) |
| Disease status before allo-HSCT | |
| Complete remission | 24 (21) |
| Relapse or persistent disease, chemosensitive | 39 (35) |
| Relapse or persistent disease, chemoresistant | 23 (20) |
| Relapse or persistent, untreated after auto-HSCT | 28 (24) |
| Donor type for allo-HSCT | |
| HLA-identical sibling | 70 (61) |
| Haploidentical sibling | 17 (14) |
| Unrelated | 27 (25) |
| Graft type used for allo-HSCT | |
| Bone marrow | 77 (68) |
| Peripheral blood | 37 (32) |
| TBI for allo-HSCT | 45 (39) |
| Posttransplantation use of growth factors, within 7 d | 84 (74) |
| GVHD prophylaxis | |
| MTX + CSA ± others | 74 (65) |
| CSA ± others | 24 (21) |
| T-cell depletion ± others | 16 (14) |
| Years of allo-HSCT | |
| 1990-1996 | 56 (49) |
| 1997-1999 | 58 (51) |
| No. centers reporting | 54 |
| Follow-up time of survivors, mo, median (range) | 43 (3-89)† |
| 75th percentile | 21 |
| 25th percentile | 58 |